Pharmaceutical

Conduit acquires three first-in-class assets from AstraZeneca 

Conduit plans to advance two assets, AZD1656 and AZD5658, into Phase II testing for autoimmune disorders.

Aug 9, 2024 - 04:00
Conduit acquires three first-in-class assets from AstraZeneca 
Conduit plans to advance two assets, AZD1656 and AZD5658, into Phase II testing for autoimmune disorders.
Read the original article

Tags:

Previous Article

CRISPR-based Casgevy is made accessible in England following NICE guidance

Next Article

Pharmacosmos ventures into oncology and merges with G1 Therapeutics

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: What the hospital-at-home movement tells us about igniting innovation in health care

Opinion: What the hospital-at-home movement tells us ab...

Aug 21, 2023

STAT+: FTC settles with Amgen over $28 billion deal for Horizon

STAT+: FTC settles with Amgen over $28 billion deal for...

Sep 2, 2023

Xenetic Biosciences forms research collaboration with TSRI

Xenetic Biosciences forms research collaboration with TSRI

Apr 12, 2023